More cases of skin and subcutaneous tissue disorders were reported for dasiglucagon relative to SoC treatment, including 2 clinically confirmed cases of necrolytic migratory erythema, a skin condition that may arise from sustained exposure to high levels of glucagon (22). The gene discussed is GCG; the disease is Erythema.